Panakeia

panakeia.ai

@Panakeia_Tech

PROBLEM

The NHS long-term plan is to identify earlier and faster cancer diagnosis as a priority area and yet as of 2022, only 65% of patients could start their treatment within 2 months, which is down from 85% in 2009. 41% of these delays are attributed to pathology; with increased cancer incidence, and increased number and complexity of tests performed in a single patient diagnosis, the current workforce is unable to deliver high quality testing services. The NHS also seeks to reach net zero by 2045, pathology testing contributes almost 9% of this carbon footprint with most emissions associated with sample collection, emissions from laboratory reagents and laboratory power.

"The DigitalHealth.London Accelerator has provided us with connections; within the NHS and AHSNs who are critical for the uptake of digital innovations as standard of care. The peer-to-peer network within our cohort has allowed us to learn from other companies facing or faced similar challenges as Panakeia allowed us to identify what works best thus creating focus in our initiatives. The Accelerator also gave us practical advice on how to communicate to customers and investors which has been influential in shaping our go to market strategy."

SUCCESSES AND IMPACT

- Panakeia obtained world's first CE/UKCA mark for determining the biomarkers straight from images of routine cancer samples, and also gained UKCA and CE marks for their second product, a colorectal tool.
- They have gone live with a paid pilot using their breast cancer tool. Prelimanary results from this pilot indicate +80% reduction in wet lab testing.
- Panakeia is in advanced stages of discussion with several NHS partners to set up additional pilot sites for across the UK.

9,000
pathologist hours/annum, time saving for every 55,000 cases

5 minutes
to interpret test results, compared to standard of 20-30 minutes

80%
reduction in Wet Lab testing

Find out more:

SOLUTION

Panakeia's AI software can analyse H&E biopsy images and instantly provide pathologists with the same information as lab-based tests.

With growing NHS adoption of digital pathology, Panakeia's solution has been built with the goal of helping Trusts meet cancer targets set out in the NHS Long Term plan.



"This can improve turnaround time for patients with cancer."

- Professor Sarah Pinder Chair, UK Breast Cancer Screening Program

WHAT'S NEXT?

Panakeia plans to further gather real world evidence on the performance of its softwares and the impact of introducing them into the mainstream NHS cancer diagnosis pathway. They will also seek to increase the depth of their softwares with more biomarkers across many more cancers in partnership with pharmaceutical companies that develop drugs for cancer.

Digital Health. London ACCELERATOR
GREATER LONDON AUTHORITY
European Union
European Regional Development Fund
Health Innovation Network South London
UCLPartners
CW+
MEDCITY